
    
      All patients having completed study ITOFD04-01 will be offered to continue to be treated with
      itopride for a period of up to one year in duration. A target of 300 patients will be
      followed up for 6 months. Of these, a target of 100 patients will be kept on treatment for an
      additional 6 months.

      Patients will need to come to the clinic for evaluations every 8 weeks during the trial.
      Evaluations done at these visits will include: lab tests, evaluation of the heartburn
      condition, and a questionnaire needed to be completed by the patient to see if the drug is
      helpful in relieving their symptoms.
    
  